Investors Research Corp Sells 375 Shares of Sanofi (NASDAQ:SNY)
Investors Research Corp reduced its stake in Sanofi (NASDAQ:SNY) by 1.3% during the first quarter, Holdings Channel.com reports. The fund owned 27,915 shares of the company’s stock after selling 375 shares during the period. Investors Research Corp’s holdings in Sanofi were worth $1,381,000 at the end of the most recent quarter.
Other institutional investors also recently bought and sold shares of the company. Cardinal Capital Management Inc. acquired a new position in shares of Sanofi in the first quarter worth approximately $25,000. Reby Advisors LLC acquired a new position in shares of Sanofi in the fourth quarter worth approximately $35,000. Arkadios Wealth Advisors acquired a new position in shares of Sanofi in the fourth quarter worth approximately $36,000. Charter Oak Capital Management LLC acquired a new position in shares of Sanofi in the fourth quarter worth approximately $40,000. Finally, JJJ Advisors Inc. lifted its stake in shares of Sanofi by 193.8% in the fourth quarter. JJJ Advisors Inc. now owns 852 shares of the company’s stock worth $41,000 after acquiring an additional 562 shares during the period. 6.93% of the stock is currently owned by institutional investors.
Several equities analysts have issued reports on SNY shares. Barclays reissued an “equal weight” rating on shares of Sanofi in a research note on Thursday, April 29th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Sanofi in a research note on Friday. UBS Group reaffirmed a “buy” rating on shares of Sanofi in a research report on Tuesday, January 19th. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Sanofi in a research report on Wednesday, February 10th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $53.00.
Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Wednesday, April 28th. The company reported $0.97 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.83 by $0.14. Sanofi had a return on equity of 24.77% and a net margin of 14.49%. The business had revenue of $8.59 billion during the quarter, compared to the consensus estimate of $8.48 billion. During the same quarter in the prior year, the company posted $1.63 earnings per share. Sanofi’s revenue was down 4.3% compared to the same quarter last year. Equities analysts expect that Sanofi will post 3.49 EPS for the current year.
The firm also recently disclosed an annual dividend, which will be paid on Wednesday, May 26th. Shareholders of record on Tuesday, May 4th will be paid a $1.9061 dividend. This represents a yield of 3.2%. The ex-dividend date of this dividend is Monday, May 3rd. This is an increase from Sanofi’s previous annual dividend of $1.21. Sanofi’s dividend payout ratio is 35.24%.
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.